Garadacimab is an activated Factor XII (FXIIa) inhibitor used to prevent attacks of hereditary angioedema. No information is available on the clinical use of garadacimab during breastfeeding. Because garadacimab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3]
加拉达西单抗是一种活化的因子XII（FXIIa）抑制剂，用于预防遗传性血管性水肿发作。目前尚无关于加拉达西单抗在母乳喂养期间临床应用的信息。由于加拉达西单抗是一种分子量约为146,000道尔顿的大蛋白质分子，乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中部分被破坏，婴儿的吸收可能极少。[2]产后至少等待2周再恢复治疗可能会减少药物向婴儿的转移。[3]
